Back to top
more

Becton, Dickinson and Company (BDX)

(Delayed Data from NYSE)

$237.84 USD

237.84
1,032,669

+0.54 (0.23%)

Updated Jul 29, 2024 04:00 PM ET

After-Market: $237.77 -0.07 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 251)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.

The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Abbott, Myomo and Apyx Medical

The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Abbott, Myomo and Apyx Medical

BD (BDX) Gets EUA, CE Mark for New Molecular Diagnostic Test

BD's (BDX) new test has the capability to detect SARS-CoV-2 and Influenza A+B in a single test.

All You Need to Know About Becton Dickinson (BDX) Rating Upgrade to Buy

Becton Dickinson (BDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Align (ALGN) Extends Invisalign G8 Availability Worldwide

Align's (ALGN) latest evolution in biomechanics is set to improve treatment predictability for frequently treated case types.

Becton Dickinson (BDX) Earnings Surpass Estimates in Q1

Each of Becton Dickinson's (BDX) core units witnesses strong revenue growth in the fiscal first quarter.

Becton Dickinson (BDX) Surpasses Q1 Earnings and Revenue Estimates

Becton Dickinson (BDX) delivered earnings and revenue surprises of 44.90% and 0.13%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Cardinal Health (CAH) to Post Q2 Earnings: What's in Store?

Cardinal Health's (CAH) fiscal second-quarter results are likely to reflect solid performance in Pharmaceutical segment.

What's in Store for Meridian Bioscience's (VIVO) Q1 Earnings?

Meridian Bioscience's (VIVO) fiscal first-quarter results are likely to reflect strong performance by Life Science business line.

AmerisourceBergen (ABC) to Post Q1 Earnings: What's in Store?

AmerisourceBergen's (ABC) fiscal first-quarter results are likely to reflect solid performance at Pharmaceutical Distribution and Other units.

Baxter (BAX) to Report Q4 Earnings: What's in the Cards?

Baxter's (BAX) fourth-quarter performance is likely to reflect growth in its Acute Therapies business.

Urmimala Biswas headshot

3 MedTech Stocks Likely to Top Estimates This Earnings Season

Strong signs of rebound in base sales volumes make us optimistic about VIVO, XRAY, and PDCO's results.

Becton Dickinson (BDX) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Becton Dickinson (BDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BD (BDX) Gears Up for Q1 Earnings: What's in the Offing?

BD's (BDX) first-quarter fiscal 2021 results are likely to reflect strong year-over-year growth in revenues from assays in its Life Sciences segment.

Becton, Dickinson's (BDX) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Becton, Dickinson and Company (BDX).

The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Becton, Dickinson and Co, Quidel and Hologic

The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Becton, Dickinson and Co, Quidel and Hologic

Urmimala Biswas headshot

Federal, Private Tie-Ups Boost COVID-19 Testing Volume

The Department of Health and Human Services (HHS) promises over $22 billion of funding.

BD (BDX) Posts Upbeat Preliminary Fiscal First Quarter Results

BD (BDX) projects its fiscal Q1 revenues to surge from the year-ago figure, primarily on the back of high demand for its COVID-19 diagnostic tests

Urmimala Biswas headshot

Testing Space in Focus Again Thanks to New Wave of Coronavirus

The resurgence in coronavirus infections is drawing attention back to the diagnostic testing space.

Why Becton Dickinson (BDX) is Poised to Beat Earnings Estimates Again

Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Here's Why You Should Invest in LHC Group (LHCG) Stock Now

LHC Group (LHCG) continues to gain traction from its broad range of services, and strategic acquisitions and joint ventures.

AMN Healthcare (AMN) Releases Solid Preliminary Q4 Revenues

AMN Healthcare (AMN) posts solid fourth-quarter 2020 revenue data on the back of strong demand for the company's services across its three segments.

The Zacks Analyst Blog Highlights: McKesson, Cardinal Health, Becton, Dickinson and Co and Hill-Rom Holdings

The Zacks Analyst Blog Highlights: McKesson, Cardinal Health, Becton, Dickinson and Co and Hill-Rom Holdings

Urmimala Biswas headshot

4 Dividend-Paying Undervalued MedTech Stocks for Gains in 2021

Here we discuss four dividend-paying value stocks, MCK, CAH, BDX and HRC, which though trading cheap now, have solid chances of a rebound in the second half of 2021.

Why Is Becton Dickinson (BDX) Up 3.5% Since Last Earnings Report?

Becton Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Should Value Investors Choose Becton, Dickinson (BDX) Stock?

Let's see if Becton, Dickinson (BDX) stock is a good choice for value-oriented investors right now from multiple angles.